patients with glioblastoma MRI perfusion in determining pseudoprogression in

We examine the role of dynamic susceptibility contrast (DSC) magnetic resonance imaging (MRI) perfusion in differentiating pseudoprogression from progression in 20 consecutive patients with treated glioblastoma. MRI perfusion was performed, and relative cerebral blood volume (rCBV), relative peak height (rPH), and percent signal recovery (PSR) were measured. Pseudoprogression demonstrated lower median rCBV (P=.009) and rPH (Pb.001), and higher PSR (P=.039) than progression. DSC MRI perfusion successfully identified pseudoprogression in patients who did not require a change in treatment despite radiographic worsening following chemoradiotherapy. © 2013 Elsevier Inc. All rights reserved.

[1]  Sean S. Park,et al.  Differentiation between intra-axial metastatic tumor progression and radiation injury following fractionated radiation therapy or stereotactic radiosurgery using MR spectroscopy, perfusion MR imaging or volume progression modeling. , 2011, Magnetic resonance imaging.

[2]  S Ekholm,et al.  Percentage Signal Recovery Derived from MR Dynamic Susceptibility Contrast Imaging Is Useful to Differentiate Common Enhancing Malignant Lesions of the Brain , 2011, American Journal of Neuroradiology.

[3]  Timothy D Johnson,et al.  Prospective Analysis of Parametric Response Map–Derived MRI Biomarkers: Identification of Early and Distinct Glioma Response Patterns Not Predicted by Standard Radiographic Assessment , 2011, Clinical Cancer Research.

[4]  William D Rooney,et al.  Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study. , 2011, International journal of radiation oncology, biology, physics.

[5]  Paul S Mischel,et al.  Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Heinrich Lanfermann,et al.  Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas , 2010, The Lancet Neurology.

[7]  D. Correa,et al.  Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Timothy D Johnson,et al.  Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  W. Mason,et al.  Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  P. Gutin,et al.  Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma , 2009, Neurology.

[11]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Law.  Advanced imaging techniques in brain tumors , 2009, Cancer imaging : the official publication of the International Cancer Imaging Society.

[13]  Bart Neyns,et al.  Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations. , 2009, Surgical neurology.

[14]  P. Sundgren.  MR Spectroscopy in Radiation Injury , 2009, American Journal of Neuroradiology.

[15]  L. Deangelis,et al.  Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Matthew S. Brown,et al.  Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. , 2009, Radiology.

[17]  Maria I. Argyropoulou,et al.  Glioma recurrence versus radiation necrosis: accuracy of current imaging modalities , 2009, Journal of Neuro-Oncology.

[18]  Susan Chang,et al.  Pseudoprogression and pseudoresponse: Challenges in brain tumor imaging , 2009, Current neurology and neuroscience reports.

[19]  J E Heiserman,et al.  Relative Cerebral Blood Volume Values to Differentiate High-Grade Glioma Recurrence from Posttreatment Radiation Effect: Direct Correlation between Image-Guided Tissue Histopathology and Localized Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging Measurements , 2009, American Journal of Neuroradiology.

[20]  Ronald L. Wolf,et al.  Posttreatment recurrence of malignant brain neoplasm: accuracy of relative cerebral blood volume fraction in discriminating low from high malignant histologic volume fraction. , 2009, Radiology.

[21]  John A Butman,et al.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M R Segal,et al.  Distinguishing Recurrent Intra-Axial Metastatic Tumor from Radiation Necrosis Following Gamma Knife Radiosurgery Using Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging , 2008, American Journal of Neuroradiology.

[23]  Dieta Brandsma,et al.  Incidence of early pseudo‐progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide , 2008, Cancer.

[24]  A. Brandes,et al.  MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Dieta Brandsma,et al.  Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. , 2008, The Lancet. Oncology.

[26]  Douglas C. Miller,et al.  Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. , 2008, Radiology.

[27]  Glyn Johnson,et al.  Comparison of region‐of‐interest analysis with three different histogram analysis methods in the determination of perfusion metrics in patients with brain gliomas , 2007, Journal of magnetic resonance imaging : JMRI.

[28]  Elias R Melhem,et al.  Intraaxial brain masses: MR imaging-based diagnostic strategy--initial experience. , 2007, Radiology.

[29]  Andrew E. Sloan,et al.  Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma , 2007, Journal of Neuro-Oncology.

[30]  Jean-Yves Delattre,et al.  Pitfalls in the diagnosis of brain tumours , 2006, The Lancet Neurology.

[31]  Thomas L Chenevert,et al.  Differentiation of recurrent brain tumor versus radiation injury using diffusion tensor imaging in patients with new contrast-enhancing lesions. , 2006, Magnetic resonance imaging.

[32]  R. Young,et al.  Brain MRI: Tumor evaluation , 2006, Journal of magnetic resonance imaging : JMRI.

[33]  B. Nan,et al.  Differentiation between brain tumor recurrence and radiation injury using MR spectroscopy. , 2005, AJR. American journal of roentgenology.

[34]  Michael H Lev,et al.  Dynamic magnetic resonance perfusion imaging of brain tumors. , 2004, The oncologist.

[35]  M. J. van den Bent,et al.  Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression , 2004, Neurology.

[36]  E. Bruera,et al.  Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  C. Eskey,et al.  Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury. , 2004, AJNR. American journal of neuroradiology.

[38]  Glyn Johnson,et al.  Dynamic, contrast‐enhanced perfusion MRI in mouse gliomas: Correlation with histopathology , 2003, Magnetic resonance in medicine.

[39]  David Hearshen,et al.  Correlations between Magnetic Resonance Spectroscopy and Image-guided Histopathology, with Special Attention to Radiation Necrosis , 2002, Neurosurgery.

[40]  Glyn Johnson,et al.  Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. , 2002, Radiology.

[41]  Glyn Johnson,et al.  Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. , 2002, Radiology.

[42]  F. Abdul-Karim,et al.  Interobserver reproducibility among neuropathologists and surgical pathologists in fibrillary astrocytoma grading , 2000, Journal of the Neurological Sciences.

[43]  R. Henry,et al.  Comparison of relative cerebral blood volume and proton spectroscopy in patients with treated gliomas. , 2000, AJNR. American journal of neuroradiology.

[44]  M Takahashi,et al.  Value of dynamic susceptibility contrast magnetic resonance imaging in the evaluation of intracranial tumors. , 1999, Topics in magnetic resonance imaging : TMRI.

[45]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  A. McKinney,et al.  Differentiation of Recurrent Glioblastoma Multiforme from Radiation Necrosis after External Beam Radiation Therapy with Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging , 2010 .

[47]  P. Box.  Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma , 2010 .

[48]  I. Kanno,et al.  Methionine PET for follow-up of radiation therapy of primary lymphoma of the brain. , 1994, Radiographics : a review publication of the Radiological Society of North America, Inc.

[49]  Marks Je,et al.  The risk of cerebral radionecrosis in relation to dose, time and fractionation. A follow-up study. , 1985, Progress in experimental tumor research.